News & Updates

Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.

In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.

Use of dupilumab results in normalization of stratum corneum (SC) lipids, which is responsible for skin barrier function, in children with atopic dermatitis (AD) within 1 to 2 months of treatment, according to a study presented at AAAAI 2024.

Individuals dealing with the stubborn scars and hyperpigmentation left behind by acne may find benefit in trifarotene cream – the newest among the new generation of topical retinoids approved for acne treatment, according to the findings of two vehicle-controlled, phase IV studies presented at AAD 2024.

Treatment with apremilast results in a significant reduction in genital psoriasis (G-PsO), as well as improvements in itch, pain, discomfort, redness, and quality of life (QoL), in patients with moderate-to-severe G-PsO who are intolerant to topical therapies, a study has shown.